Abstract
The function of the platelet collagen receptor, 65-kDa, specific for type I collagen (CI), in eukaryotic cells remains elusive. In order to examine the effect of posttranslational modification of the receptor, we have made a construct, which contains the 65-kDa cDNA ligated into pcDNA3 (eukaryotic expression vector) by using standard cloning methodologies. The construct was transfected into CHO (CHO-65) cells, which expressed the protein, detectable by immunoblots [using the anti-65kDa antibodies (65-Ab)], and flow cytometry confirmed expression on the cell surface. A binding assay was used to evaluate the interaction of the expressed protein with CI. A chemically synthesized hybrid peptide (cHyB) containing the active peptides derived from the platelet receptors for types I and III collagen (9 amino acids each with a linker of 10 amino acid residues) inhibited the binding of the 65-Ab and FITC-CI on the CHO-65 cells. These results suggest that the 65-kDa proteins play a role in the interaction with CI and could potentially lead to new therapeutic development for an anti-platelet agent.
Keywords: Collagen, platelet, platelet aggregation inhibitor, flow cytometry, thrombosis
Cardiovascular & Hematological Disorders-Drug Targets
Title: Effect of a Hybrid Peptide Derived from Platelet Type I and Type III Collagen Receptors on CHO-65 Cells
Volume: 9 Issue: 3
Author(s): Thomas M. Chiang
Affiliation:
Keywords: Collagen, platelet, platelet aggregation inhibitor, flow cytometry, thrombosis
Abstract: The function of the platelet collagen receptor, 65-kDa, specific for type I collagen (CI), in eukaryotic cells remains elusive. In order to examine the effect of posttranslational modification of the receptor, we have made a construct, which contains the 65-kDa cDNA ligated into pcDNA3 (eukaryotic expression vector) by using standard cloning methodologies. The construct was transfected into CHO (CHO-65) cells, which expressed the protein, detectable by immunoblots [using the anti-65kDa antibodies (65-Ab)], and flow cytometry confirmed expression on the cell surface. A binding assay was used to evaluate the interaction of the expressed protein with CI. A chemically synthesized hybrid peptide (cHyB) containing the active peptides derived from the platelet receptors for types I and III collagen (9 amino acids each with a linker of 10 amino acid residues) inhibited the binding of the 65-Ab and FITC-CI on the CHO-65 cells. These results suggest that the 65-kDa proteins play a role in the interaction with CI and could potentially lead to new therapeutic development for an anti-platelet agent.
Export Options
About this article
Cite this article as:
Chiang M. Thomas, Effect of a Hybrid Peptide Derived from Platelet Type I and Type III Collagen Receptors on CHO-65 Cells, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187152909789007089
DOI https://dx.doi.org/10.2174/187152909789007089 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets <i>Tylophora hirsuta</i> (Wall.) Extracts Ameliorate Diabetes Associated with Inflammation in Alloxan-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Preparation and Characterization of a Conduit for Peripheral Nerve Regeneration
Current Applied Polymer Science Clinical Efficacy of Cerebrolysin and Cerebrolysin plus Nootropics in the Treatment of Patients with Acute Ischemic Stroke in Vietnam
CNS & Neurological Disorders - Drug Targets Preface
Current Cardiology Reviews Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Activity and Structure Elucidation of Ceramides
Current Bioactive Compounds Immunometabolism Dysfunction in the Pathophysiology and Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry MiR-101 Attenuates Myocardial Infarction-induced Injury by Targeting DDIT4 to Regulate Autophagy
Current Neurovascular Research Role of Mitochondria and Other ROS Sources in Hyperthyroidism-Linked Oxidative Stress
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Preface:
Current Vascular Pharmacology Technological Advancement in ω-3 Fatty Acids: Their Therapeutic Functions and Novel Delivery Strategies
Current Pharmaceutical Design Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome
Current Vascular Pharmacology Inflammatory Molecular Mediators and Pathways Involved in Vascular Aging and Stroke: A Comprehensive Review
Current Medicinal Chemistry Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research